{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T19:33:35Z","timestamp":1777923215120,"version":"3.51.4"},"reference-count":23,"publisher":"SAGE Publications","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Microbial Drug Resistance"],"published-print":{"date-parts":[[2025,1]]},"abstract":"<jats:p>Even if in the past years new effective, safe, and orally administrable drugs are available to create shorter regimens, drug-resistant (DR) tuberculosis (TB) treatment remains a critical issue and a major challenge faced by clinicians worldwide. We present the first case of transborder pulmonary pre-extensively drug-resistant (pre-XDR)-TB treated in Italy with the bedaquiline-pretomanid-linezolid regimen. Diagnosis and treatment were started in Ukraine, and, after a month of treatment, due to the Russo-Ukrainian war, the patient moved to Italy, where the diagnosis was confirmed both by genotypic and phenotypic drug susceptibility tests, and treatment continued. In this short report, we highlight challenges and future opportunities to improve the clinical management of patient with DR-TB.<\/jats:p>","DOI":"10.1089\/mdr.2024.0045","type":"journal-article","created":{"date-parts":[[2024,12,12]],"date-time":"2024-12-12T09:35:22Z","timestamp":1733996122000},"page":"12-15","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":1,"title":["TB Anywhere, TB Everywhere. The First Case of pre-Extensively Drug Resistant Tuberculosis Treated with BPaL in Italy: Challenges and Opportunities for Transborder Collaboration"],"prefix":"10.1177","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-2092-7501","authenticated-orcid":false,"given":"Giovanni","family":"Fumagalli","sequence":"first","affiliation":[{"name":"Regional TB Reference Centre, Villa Marelli Institute, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy."},{"name":"StopTB Italia ODV, Milan, Italy."},{"name":"Department of Physiopathology and Transplantation, Universit\u00e0degliStudi di Milano, Milan, Italy."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Niccol\u00f2","family":"Riccardi","sequence":"additional","affiliation":[{"name":"Regional TB Reference Centre, Villa Marelli Institute, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy."},{"name":"Infectious Diseases Unit, AziendaOspedaliero-Universitaria Pisana, Pisa, Italy."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gaia","family":"Catalano","sequence":"additional","affiliation":[{"name":"Vita-Salute San Raffaele University, Milan, Italy."},{"name":"Infectious Diseases, IRCCS San Raffaele Scientific Institute, Milan, Italy."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maurizio","family":"Ferrarese","sequence":"additional","affiliation":[{"name":"Regional TB Reference Centre, Villa Marelli Institute, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy."},{"name":"StopTB Italia ODV, Milan, Italy."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alice Claudia","family":"Repossi","sequence":"additional","affiliation":[{"name":"Regional TB Reference Centre, Villa Marelli Institute, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy."},{"name":"StopTB Italia ODV, Milan, Italy."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luigi R.","family":"Codecasa","sequence":"additional","affiliation":[{"name":"Regional TB Reference Centre, Villa Marelli Institute, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy."},{"name":"StopTB Italia ODV, Milan, Italy."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2025,1,8]]},"reference":[{"key":"e_1_3_4_2_2","unstructured":"Global tuberculosis report 2023. World Health Organization: Geneva; 2023."},{"key":"e_1_3_4_3_2","volume-title":"Module 4: Treatment - Drug-Resistant Tuberculosis Treatment, 2022 update","author":"WHO consolidated guidelines on tuberculosis","year":"2022","unstructured":"WHO consolidated guidelines on tuberculosis. Module 4: Treatment - Drug-Resistant Tuberculosis Treatment, 2022 update. World Health Organization: Geneva; 2022."},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2117166"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-015-0279-6"},{"key":"e_1_3_4_6_2","volume-title":"Tuberculosis Surveillance and monitoring in Europe 2023\u20132021 data","author":"European Centre for Disease Prevention and Control, WHO Regional Office for Europe","year":"2023","unstructured":"European Centre for Disease Prevention and Control, WHO Regional Office for Europe. Tuberculosis Surveillance and monitoring in Europe 2023\u20132021 data: European Centre for Disease Prevention and Control and Copenhagen: WHO Regional Office for Europe: Stockholm; 2023."},{"issue":"4","key":"e_1_3_4_7_2","doi-asserted-by":"crossref","first-page":"e1218","DOI":"10.1002\/hsr2.1218","article-title":"Public health concerns about Tuberculosis caused by Russia\/Ukraine conflict","volume":"6","author":"Paul IK","year":"2023","unstructured":"Paul IK, , Nchasi G, , Bulimbe DB, et al. Public health concerns about Tuberculosis caused by Russia\/Ukraine conflict. Health Sci Rep, 2023; 6(4):e1218; doi: 10.1002\/hsr2.1218","journal-title":"Health Sci Rep"},{"issue":"24","key":"e_1_3_4_8_2","doi-asserted-by":"crossref","first-page":"2300284","DOI":"10.2807\/1560-7917.ES.2023.28.24.2300284","article-title":"Tuberculosis in times of war and crisis: Epidemiological trends and characteristics of patients born in Ukraine, Germany, 2022","volume":"28","author":"Hauer B","year":"2023","unstructured":"Hauer B, , Kr\u00f6ger S, , Haas W, , Brodhun B. Tuberculosis in times of war and crisis: Epidemiological trends and characteristics of patients born in Ukraine, Germany, 2022. Euro Surveill, 2023; 28(24):2300284.","journal-title":"Euro Surveill"},{"key":"e_1_3_4_9_2","volume-title":"National Institutes of Health","author":"US Department of Health and Human Services","year":"2018","unstructured":"US Department of Health and Human Services. \u201cCommon terminology criteria for adverse events (CTCAE) version 5.0.\u201dIn: National Institutes of Health, National Cancer Institute. 4(3) (2018)."},{"issue":"1","key":"e_1_3_4_10_2","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s12941-016-0156-y","article-title":"Efficacy and safety profile of linezolid in the treatment of Multidrug-Resistant (MDR) and Extensively Drug-Resistant (XDR) tuberculosis: A systematic review and meta-analysis","volume":"15","author":"Agyeman AA","year":"2016","unstructured":"Agyeman AA, , Ofori-Asenso R. Efficacy and safety profile of linezolid in the treatment of Multidrug-Resistant (MDR) and Extensively Drug-Resistant (XDR) tuberculosis: A systematic review and meta-analysis. Ann Clin Microbiol Antimicrob, 2016 Jun 22;15(1):41; doi: 10.1186\/s12941-016-0156-y","journal-title":"Ann Clin Microbiol Antimicrob"},{"issue":"10","key":"e_1_3_4_11_2","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1056\/NEJMoa1901814","article-title":"Treatment of highly drug-resistant pulmonary tuberculosis","volume":"382","author":"Conradie F","year":"2020","unstructured":"Conradie F, , Diacon AH, , Ngubane N, et al. Nix-TB Trial Team. Treatment of highly drug-resistant pulmonary tuberculosis. N Engl J Med, 2020; 382(10):893\u2013902; doi: 10.1056\/NEJMoa1901814","journal-title":"N Engl J Med"},{"issue":"4","key":"e_1_3_4_12_2","doi-asserted-by":"crossref","first-page":"ofad177","DOI":"10.1093\/ofid\/ofad177","article-title":"At long last: Short, all-oral regimens for multidrug-resistant tuberculosis in the United States","volume":"10","author":"Sinha P","year":"2023","unstructured":"Sinha P, , Jacobson KR, , Horsburgh CRJr, et al. At long last: Short, all-oral regimens for multidrug-resistant tuberculosis in the United States. Open Forum Infect Dis, 2023; 10(4):ofad177; doi: 10.1093\/ofid\/ofad177","journal-title":"Open Forum Infect Dis"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2019.03.036"},{"issue":"6","key":"e_1_3_4_14_2","doi-asserted-by":"crossref","first-page":"1901522","DOI":"10.1183\/13993003.01522-2019","article-title":"Surveillance of adverse events in the treatment of drug-resistant tuberculosis: First global report","volume":"54","author":"Borisov S","year":"2019","unstructured":"Borisov S, , Danila E, , Maryandyshev A, et al. Surveillance of adverse events in the treatment of drug-resistant tuberculosis: First global report. Eur Respir J, 2019; 54(6):1901522; doi: 10.1183\/13993003.01522-2019","journal-title":"Eur Respir J"},{"issue":"8","key":"e_1_3_4_15_2","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.3201\/eid2608.191499","article-title":"Linezolid-associated neurologic adverse events in patients with multidrug-resistant tuberculosis, France","volume":"26","author":"Jaspard M","year":"2020","unstructured":"Jaspard M, , Butel N, , El Helali N, et al. Linezolid-associated neurologic adverse events in patients with multidrug-resistant tuberculosis, France. Emerg Infect Dis, 2020; 26(8):1792\u20131800; doi: 10.3201\/eid2608.191499","journal-title":"Emerg Infect Dis"},{"issue":"10","key":"e_1_3_4_16_2","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1093\/cid\/ciab699","article-title":"Proposed linezolid dosing strategies to minimize adverse events for treatment of extensively drug-resistant tuberculosis","volume":"74","author":"Imperial MZ","year":"2022","unstructured":"Imperial MZ, , Nedelman JR, , Conradie F, et al. Proposed linezolid dosing strategies to minimize adverse events for treatment of extensively drug-resistant tuberculosis. Clin Infect Dis, 2022; 74(10):1736\u20131747; doi: 10.1093\/cid\/ciab699","journal-title":"Clin Infect Dis"},{"issue":"3","key":"e_1_3_4_17_2","doi-asserted-by":"crossref","first-page":"e947","DOI":"10.1093\/cid\/ciac485","article-title":"Association between increased linezolid plasma concentrations and the development of severe toxicity in multidrug-resistant tuberculosis treatment","volume":"76","author":"Eimer J","year":"2023","unstructured":"Eimer J, , Fr\u00e9chet-Jachym M, , Le D\u00fb D, et al. LZDM group. Association between increased linezolid plasma concentrations and the development of severe toxicity in multidrug-resistant tuberculosis treatment. Clin Infect Dis, 2023; 76(3):e947\u2013e956; doi: 10.1093\/cid\/ciac48516.","journal-title":"Clin Infect Dis"},{"issue":"10","key":"e_1_3_4_18_2","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1080\/14740338.2019.1648429","article-title":"A safety evaluation of bedaquiline for the treatment of multi-drug resistant tuberculosis","volume":"18","author":"Cohen K","year":"2019","unstructured":"Cohen K, , Maartens G. A safety evaluation of bedaquiline for the treatment of multi-drug resistant tuberculosis. Expert Opin Drug Saf, 2019; 18(10):875\u2013882; doi: 10.1080\/14740338.2019.1648429","journal-title":"Expert Opin Drug Saf"},{"issue":"1","key":"e_1_3_4_19_2","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1186\/s13063-023-07701-6","article-title":"Evaluating newly approved drugs in combination regimens for multidrug-resistant tuberculosis with fluoroquinolone resistance (endTB-Q): Study protocol for a multi-country randomized controlled trial","volume":"24","author":"Patil SB","year":"2023","unstructured":"Patil SB, , Tamirat M, , Khazhidinov K, et al. Evaluating newly approved drugs in combination regimens for multidrug-resistant tuberculosis with fluoroquinolone resistance (endTB-Q): Study protocol for a multi-country randomized controlled trial. Trials, 2023; 24(1):773; doi: 10.1186\/s13063-023-07701-6","journal-title":"Trials"},{"issue":"10","key":"e_1_3_4_20_2","first-page":"1737","article-title":"Long-term genexpert positivity after treatment for pulmonary tuberculosis","volume":"7","author":"Costantini L","year":"2020","unstructured":"Costantini L, , Marando M, , Gianella P. Long-term genexpert positivity after treatment for pulmonary tuberculosis. Eur J Case Rep Intern Med, 2020; 7(10):1737; doi: 10.12890\/2020_001737","journal-title":"Eur J Case Rep Intern Med"},{"issue":"12","key":"e_1_3_4_21_2","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/j.arbres.2022.07.012","article-title":"Rapid diagnosis of XDR and Pre-XDR TB: A systematic review of available tools","volume":"58","author":"Saderi L","year":"2022","unstructured":"Saderi L, , Puci M, , Di Lorenzo B, et al. Rapid diagnosis of XDR and Pre-XDR TB: A systematic review of available tools. Arch Bronconeumol, 2022; 58(12):809\u2013820; doi: 10.1016\/j.arbres.2022.07.012","journal-title":"Arch Bronconeumol"},{"issue":"12","key":"e_1_3_4_22_2","doi-asserted-by":"crossref","first-page":"2782","DOI":"10.3390\/pharmaceutics15122782","article-title":"Impact of whole-genome sequencing of mycobacterium tuberculosis on treatment outcomes for MDR-TB\/XDR-TB: A systematic review","volume":"15","author":"Hazra D","year":"2023","unstructured":"Hazra D, , Lam C, , Chawla K, et al. Impact of whole-genome sequencing of mycobacterium tuberculosis on treatment outcomes for MDR-TB\/XDR-TB: A systematic review. Pharmaceutics, 2023; 15(12):2782; doi: 10.3390\/pharmaceutics15122782PMC10747601","journal-title":"Pharmaceutics"},{"issue":"4","key":"e_1_3_4_23_2","doi-asserted-by":"crossref","first-page":"e122","DOI":"10.1016\/S1473-3099(22)00875-1","article-title":"Clinical implications of molecular drug resistance testing for mycobacterium tuberculosis: A 2023 TBnet\/RESIST-TB consensus statement","volume":"23","author":"Dom\u00ednguez J","year":"2023","unstructured":"Dom\u00ednguez J, , Boeree MJ, , Cambau E, et al. TBnet and RESIST-TB networks. Clinical implications of molecular drug resistance testing for mycobacterium tuberculosis: A 2023 TBnet\/RESIST-TB consensus statement. Lancet Infect Dis, 2023; 23(4):e122\u2013e137; doi: 10.1016\/S1473-3099(22)00875-1","journal-title":"Lancet Infect Dis"},{"issue":"3","key":"e_1_3_4_24_2","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00839-2021","article-title":"Outbreak of pre- and extensively drug-resistant tuberculosis in northern italy: Urgency of crossborder, multi-dimensional, surveillance systems","volume":"58","author":"Villa S","year":"2021","unstructured":"Villa S, , Tagliani E, , Borroni E, et al. Outbreak of pre- and extensively drug-resistant tuberculosis in northern italy: Urgency of crossborder, multi-dimensional, surveillance systems. Eur Respir J, 2021; 58(3); doi: 10.1183\/13993003.00839-2021","journal-title":"Eur Respir J"}],"container-title":["Microbial Drug Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/mdr.2024.0045","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/mdr.2024.0045","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/mdr.2024.0045","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T20:41:36Z","timestamp":1777668096000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/full\/10.1089\/mdr.2024.0045"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["10.1089\/mdr.2024.0045"],"URL":"https:\/\/doi.org\/10.1089\/mdr.2024.0045","relation":{},"ISSN":["1076-6294","1931-8448"],"issn-type":[{"value":"1076-6294","type":"print"},{"value":"1931-8448","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1]]}}}